Agreement Terminated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2026 Amgen Inc. (Exact name of registrant as specified in its charter)   Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) One Amgen Center Drive   Thousand Oaks   California   91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (805) 447-1000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)    ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))    ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   AMGN   The Nasdaq Stock Market LLC 2.000% Senior Notes due 2026   AMGN26   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.02 Termination of a Material Definitive Agreement. On January 30, 2026, Amgen Inc. (the “ Company ”) entered into a Termination Agreement (the “ Termination Agreement ”) with Kyowa Kirin Co., Ltd. (“ Kyowa Kirin ”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “ License and Collaboration Agreement ”). The termination of the License and Collaboration Agreement will become effective upon receipt of regulatory approval. The foregoing description of the Termination Agreement and the termination of the License and Collaboration Agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.   10.1    Termination Agreement, dated January 30, 2026, by and between Amgen Inc. and Kyowa Kirin Co., Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential). 104    Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       AMGEN INC. Date: January 30, 2026     By:    /s/ Jonathan P. Graham     Name:   Jonathan P. Graham     Title:   Executive Vice President and General Counsel and Secretary